NEWFlashcards for any set of questions, quick-reference tables for breast, lung and prostate, and a month of access for every colleague you refer. See what changed

Skin: Adjuvant immunotherapy stage III (CheckMate 238)

Free question published 04 November 2026

SkinAdjuvant immunotherapy stage III (CheckMate 238)

A 58-year-old woman has fully resected stage IIIC cutaneous melanoma that is BRAF wild-type. She has no significant autoimmune history and good performance status. The MDT is choosing between adjuvant anti-PD-1 and adjuvant ipilimumab. Citing CheckMate 238, which statement best supports the recommended adjuvant choice?

  1. AAdjuvant ipilimumab provided longer recurrence-free survival than nivolumab
  2. BAdjuvant nivolumab provided longer recurrence-free survival than ipilimumab with less toxicity
  3. CNeither agent improved recurrence-free survival over observation
  4. DAdjuvant therapy is contraindicated in BRAF wild-type disease
  5. EThe two agents were equivalent for recurrence-free survival but nivolumab was more toxic

Why B is correct

CheckMate 238 randomised resected stage IIIB-C/IV melanoma to adjuvant nivolumab or ipilimumab and demonstrated superior recurrence-free survival with nivolumab (for example 4-year RFS 51.7% vs 41.2%) together with a substantially better toxicity profile. Adjuvant anti-PD-1 (nivolumab) is therefore preferred over ipilimumab, and is suitable for this BRAF wild-type patient.

And why the others are not

  • AIncorrect: ipilimumab was the inferior comparator for recurrence-free survival in this trial.
  • CIncorrect: both were active adjuvant agents; the trial compared them head-to-head rather than against observation, and anti-PD-1 benefit over placebo is established elsewhere.
  • DIncorrect: anti-PD-1 immunotherapy is effective regardless of BRAF status, so BRAF wild-type disease does not preclude adjuvant treatment.
  • EIncorrect: the agents were not equivalent; nivolumab was superior for RFS and less toxic, not more.

Source CheckMate 238 - Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma — Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824-1835; Larkin J, et al. 4-year results. Lancet Oncol. 2020.

Sitting in February? Follow the twenty-week plan.

2,500+ cited questions like this one are waiting in the vault.

See plans and pricing